Podcast PX Pulse

CAB-LA is a Highly Effective HIV Prevention Option; Now what?


Long-acting injectable cabotegravir (CAB-LA) is a promising new option for HIV prevention. In 2020, early results from two trials—HPTN 083 and HPTN 084—showed CAB-LA was safe and highly effective at preventing HIV when compared to daily oral TDF/FTC (Truvada) in men who have sex with men (MSM), transgender (TG) women and cisgender women. Now what? What questions remain unanswered and what support is needed now to make the growing range of prevention options feasible choices for people who may want and need them?

Subscribe to this Podcast

Cisgender Women
Gay and Bisexual Men Who Have Sex with Men
Transgender Women
Tracking and Translating the Field